StockData
Acumen Pharmaceuticals, Inc. logo

Acumen Pharmaceuticals, Inc. (ABOS) stock

ABOSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 26, 2026Score 2/30
$0.23+0.01 (+6.53%)

Close on Nov 17, 2026Market cap $16.64MP/E –Yield –

Acumen Pharmaceuticals operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Acumen Pharmaceuticals's operating cash flow for the twelve months ending Sep 30, 2026 was -$87.95M. For fiscal 2025 it was -$115.54M. The highest annual figure on record is -$7.45M in fiscal 2020.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$115.54M–
FY2024Dec 31, 2024-$86.22M–
FY2023Dec 31, 2023-$43.06M–
FY2022Dec 31, 2022-$35.15M–
FY2021Dec 31, 2021-$17.96M–
FY2020Dec 31, 2020-$7.45M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026-$26.65M–
Q2 FY2026Jun 30, 2026-$18.08M–
Q1 FY2026Mar 31, 2026-$24.13M–
Q4 FY2025Dec 31, 2025-$19.10M–
Q3 FY2025Sep 30, 2025-$30.49M–
Q2 FY2025Jun 30, 2025-$31.83M–
Q1 FY2025Mar 31, 2025-$34.12M–
Q4 FY2024Dec 31, 2024-$27.22M–
Q3 FY2024Sep 30, 2024-$24.60M–
Q2 FY2024Jun 30, 2024-$16.55M–
Q1 FY2024Mar 31, 2024-$17.86M–
Q4 FY2023Dec 31, 2023-$8.31M–
Q3 FY2023Sep 30, 2023-$12.91M–
Q2 FY2023Jun 30, 2023-$11.67M–
Q1 FY2023Mar 31, 2023-$10.18M–
Q4 FY2022Dec 31, 2022-$11.20M–
Q3 FY2022Sep 30, 2022-$9.18M–
Q2 FY2022Jun 30, 2022-$6.47M–
Q1 FY2022Mar 31, 2022-$8.30M–
Q4 FY2021Dec 31, 2021-$3.64M–
Q3 FY2021Sep 30, 2021-$7.69M–
Q2 FY2021Jun 30, 2021-$4.26M–
Q1 FY2021Mar 31, 2021-$2.37M–
Q4 FY2020Dec 31, 2020-$2.86M–
Q3 FY2020Sep 30, 2020-$1.28M–

More Acumen Pharmaceuticals figures

See a number that looks wrong?